Paola S. Ravenda
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer.
Journal: JAMA network open
Published: February 16, 2023
Observational Study on Antibody Response to COVID-19 Vaccines in PAtients with Gastro-Entero-PanCreatic Cancers and NeuroendocrIne NeoplAsms on Systemic TreatmEnts (VACCINATE).
Journal: Biomedicines
Published: January 03, 2023
Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center.
Journal: Therapeutic advances in medical oncology
Published: February 09, 2020
Intensity-modulated radiotherapy (IMRT) in the treatment of squamous cell anal canal cancer: acute and early-late toxicity, outcome, and efficacy.
Journal: International journal of colorectal disease
Published: January 26, 2020
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier).
Journal: Cancer management and research
Published: December 06, 2018
Transarterial Embolization with Small-Size Particles Loaded with Irinotecan for the Treatment of Colorectal Liver Metastases: Results of the MIRACLE III Study.
Journal: Cardiovascular and interventional radiology
Published: February 15, 2018
High-risk human papillomavirus in anal squamous cell carcinoma: a 'conservative' leading role.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 29, 2017
Anal human papillomavirus infection: prevalence, diagnosis and treatment of related lesions.
Journal: Expert review of anti-infective therapy
Published: April 07, 2016
Treatments for colorectal liver metastases: A new focus on a familiar concept.
Journal: Critical reviews in oncology/hematology
Published: March 07, 2016
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.
Journal: Nature medicine
Published: December 14, 2015
Last Updated: 09/26/2026